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Abstract
Summary We analyzed 12-month compliance for all ten
oral osteoporosis drugs in the Netherlands by medication
possession ratio (MPR≥80%) in 105,506 patients, and
persistence in 8,626 starters indicated high MPR (91%),
low persistence (43%), and no restart in 78% of the
stoppers after 18 months.
Introduction We studied compliance and persistence for all
available oral osteoporosis medications on a national scale
in the Netherlands.
Methods We analyzed the IMS Health’s longitudinal pre-
scription database, which represents 73% of all pharmacies
inthe Netherlands.Twelve-month compliancewas measured
by medication possession ratio (MPR) in a cross-sectional
cohort of 105,506 patients who received at least three
prescriptions. Twelve-month persistence (no gap in refills
for >6 months) was measured in all 8,626 consecutive
patients starting therapy, with a further follow-up in non-
persistent patients during an additional 18 months for
evaluation of switching, restart, or definitive stopping oral
medication. Multivariate logistic regression analysis was
used to analyze the odds ratios (ORs) with 95% confidence
intervals (CI) of characteristics of non-persistence.
Results MPR of ≥80% was found in 91% of patients.
Persistence was 43% (range, 29–52%). Persistence was
related to age >60 years (ORs, 1.41 to 1.64), pharmacy
outside very dense urban area (ORs, 1.39 to 1.44),
additional use of calcium and/or vitamin D supplementation
(OR, 1.26 and CI, 1.13, 1.39) and use of glucocorticoids
(OR, 0.65 and CI, 0.59, 0.72) or cardiovascular medication
(OR, 0.88 and CI, 0.79, 0.97). Of non-persistent patients,
22% restarted within 18 months with oral osteoporosis
drugs.
Conclusions One-year compliance for all available oral
osteoporosis medications was high, but 1-year persistence
was low. Most stoppers did not restart or switch during an
additional 18-month follow-up. These data indicate a major
failure to adequately treat patients at high risk for fractures
in daily practice.
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Introduction
After the age of 50 years, more than one in two women and
one in five men will suffer a fracture during their remaining
lifetime [1, 2]. Fractures result in high economic costs,
morbidity, disability, mortality, and subsequent fractures,
which are highest immediately after fracture, but remain
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that 20% to 50% of fractures related to osteoporosis can be
prevented by specific osteoporosis drug treatment as
reported in randomized controlled clinical trials (RCTs).
However, there is a large discrepancy between the relative
high adherence to osteoporosis medication in RCTs (e.g., in
the Fracture Intervention Trial in postmenopausal women
with increased fracture risk, compliance of >74% was
found in 96% of the participants [8]), and the poor
adherence in daily clinical practice [9, 10]. The main
components of adherence are compliance (how correctly, in
terms of dose and frequency, a patient takes the available
medication) and persistence (how long a patient receives
therapy after initiating treatment), but these definitions vary
among publications [11].
We used the following definitions. Compliance was
defined as the extent to which a patient acts in accordance
with the prescribed interval and dose of a dosing regimen,
and persistence as the duration of time from initiation to
discontinuation of therapy and adherence as a general term
encompassing both persistence and compliance [12].
Compliance and persistence for medications used in chronic
diseases are notoriously poor, and osteoporosis is no
exception. About 50% of patients fail to comply or persist
with osteoporosis treatment within 1 year [13, 14]. Most
importantly, low compliance and persistence result in a
significantly lower anti-fracture effect, as has been shown
for bisphosphonates [9, 13-24]. Although cut-off points are
arbitrary and could lead to loss of information, a medication
possession ratio (MPR) of 80% or greater is commonly
regarded as the lowest threshold for optimal efficacy in the
prevention of fractures [14, 19].
Little is known about the extent to which patients after
discontinuing treatment in the routine care restart or switch
to other drugs in the same class. In one retrospective study,
it was found that of the patients who stopped therapy for at
least 6 months, an estimated 30% restarted treatment within
6 months, and 50% restarted within 2 years [25]. Factors
that are related to low compliance and/or persistence in
daily practice are difficult to identify [13]. Insofar they have
been studied, they include characteristics related to the drug
(such as adverse events, cost, and dosing), to the patient
(such as education, information, co-morbidity, and co-
medication), and to the doctor (such as follow-up strategies
and adherence to osteoporosis guidelines) [20, 26, 27].
In a retrospective, longitudinal, large prescription data-
base covering more than 70% of the Dutch population, we
studied adherence in terms of 12-month compliance and
persistence, characteristics of non-persistent patients (gender,
age, living area, co-morbidity, co-medication, and prescriber)
and analyzed during 18 months after stopping the extent of
restart or switch to other osteoporosis medication in non-
persistent patients.
Methods
Data source
The study was carried out in the routine practice setting in
the Netherlands. Data were obtained from the IMS
Health’s longitudinal prescription database (LRx, affiliate
Capelle ad Ijssel, Netherlands). This source consists of
anonymized patient longitudinal prescription records from
a representative sample of pharmacies and dispensing
general practitioners (GPs) with a coverage of 73% of the
retail dispensing corresponding to the drug consumption
of 11.9 million of the 16.5 million Dutch inhabitants. In
the Netherlands, ambulant patients visiting a specialist
also receive their medication via the retail channel, and so
this dispensing is also covered by the database. The
computerized drug-dispensing histories contain complete
data concerning the dispensed drug, type of prescriber,
dispensing date, dispensed amount, prescribed dose
regimen, and the prescription length. Data for each patient
were anonymized in each pharmacy independently without
linkage of the dispensed prescriptions to the same unique
patient across pharmacies.
Patients in Netherlands are usually loyal to one pharmacy
[28]. Because moving to other home (e.g., nursing home)
or dying could bias the persistence, we performed an
additional persistence analysis and compared persistence
of osteoporosis medication in patients who did and did
not refill other medications.
All oral drugs which are prescribed for osteoporosis in
the Netherlands were evaluated (Table 1). No distinction
between alendronate 10 and 70 mg branded or generic
could be made because pharmacies are free to dispense the
variant they prefer irrespective of the doctors prescribing,
but Fosavance® could be identified. Compliance and
persistence for calcium and vitamin D supplements were
not analyzed.
Analysis of adherence included two distinct, albeit
overlapping, components; compliance (in a cohort of non-
switching and persistent patients), and persistence (in a
cohort of patients who started osteoporosis medication) and
was further evaluated in non-persistent patients for subse-
quent switch or definite non-persistence.
Compliance
Compliance was expressed as the medication possession
ratio (MPR), calculated by dividing the supply of drugs in
treatment days by the interval time between first and last
date of dispensing [29, 30]. Over a period of 1 year
(November 2007–October 2008), all patients who started or
who were already previously on osteoporosis medication
and who did not switch between the studied osteoporosis
1538 Osteoporos Int (2011) 22:1537–1546drugs and had at least three prescriptions were selected.
This last restriction was chosen for reasons of reducing
individual variability of dispensing rate. As a rule in the
Netherlands, one prescription covers maximally 90 days. In
this analysis, we started with 153,903 patients and ended
with 105,506 patients. A total of 12,263 patients were lost
because of drug switching and 36,134, because they
received less than three prescriptions.
Persistence
The 1-year rates of persistence with treatment were defined
as the percentage of patients who used the drug for at least
365 days without failure to receive a refill and without
switching to another oral osteoporosis drug. Such evalua-
tion of persistence provides insight into the duration of
treatment supply [11, 30, 31]. The treatment episode was
defined as the period of time in which the patient
continuously used the specific drug. If the gap between
consecutive dispensing dates was more than 6 months, the
last prescription of the drug before this gap was considered
as the last prescription. The treatment period lasts from start
date till end date of this last prescription using the therapy
duration of this last prescription as recorded by the
pharmacy. Each patient was judged during 365 days as
being either persistent (still on medication on drug of start)
or non-persistent (no longer using this drug of start).
Persistence after 1 year was calculated and used to correlate
with factors that could influence 1-year persistence. Patients
who stopped the initial drug during the first half year were
followed during an additional 18 months.
For the analysis of 12 months’ persistence, data were
obtained from the LRx database between September 2006
and October 2008. All consecutive patients starting one of
the available oral osteoporosis drugs between March and
May 2007 and not receiving prescriptions of that particular
drug during at least 6 months previous to the start were
included. This timing selection allowed in all patients to
include a 6-month follow-up (trailing) period and a 6-
month lookback period (Fig. 1).
In this analysis, we started with a total of 171,293 patients
having any osteoporosis medication of which 168,749
received oral medication. Most patients (n=99,148) received
their first prescription in our prescription database in the
lookback period or during reporting and trailing period (n=
60,975), which results in 8,626 starters for the analysis of
persistence. Moving to another address (e.g., nursing home)
or death during follow-up could have biased the persistence
results. Therefore, persistence was also separately analyzed
in patients who also continued other than osteoporosis
medications at the end of the period.
Determinants of persistence
In order to explore factors that could be related to 12-month
persistence, three groups of possible determinants were re-
Table 1 MPR analysis of mean 12-month compliance with three or more prescriptions of one of ten oral osteoporosis drugs in 105,506 patients
Brand (where applicable) Content in molecule(s) Patients V% MPR>80%
Actokit® Risedronic acid 35 mg weekly and calcium 6 days 4,954 4.7% 93.1%
a
Actonel® 35 mg Risedronic acid 35 mg weekly 24,866 23.6% 91.5%
b
Actonel® 5 mg Risedronic acid 5 mg daily 1,010 1.0% 91.6%
b
Alendronic acid 10 mg Alendronic acid 10 mg daily branded or generic 3,101 2.9% 92.2%
a
Alendronic acid 70 mg Alendronic acid 70 mg weekly branded or generic 55,195 52.3% 91.2%
b
Bonviva® tablet Ibandronic acid 150 mg monthly 3,279 3.1% 89.0%
c
Didrokit® Etidronic acid cyclic and calcium 2,538 2.4% 85.7%
c
Evista® Raloxifene 60 mg daily 1,331 1.3% 91.5%
b
Fosavance® Alendronic acid 70 mg weekly & 2,800 IU vitamin D3 8,279 7.8% 92.3%
a
Protolos® Strontium ranelate 2 g daily 953 0.9% 79.1%
c
Total of ten products 105,506 100.0% 91.2%
aHigher MPR (p<0.05)
bReference MPR
cLower MPR (p<0.05)
Time (months)
123456 7 89 1 0 1 1 1 2 1 3 1 4 1 5 1 6 1 7 1 8 1 92 0 2 1 2 2 2 3 2 4
lookback period Start <------ reporting period --------> trailing period
drugs in lookback period drugs trailing period
Fig. 1 Analysis of 12 months’
persistence
Osteoporos Int (2011) 22:1537–1546 1539corded. First, we used the patient-depending information
like age, gender, sex, and rurality of the patients’ pharmacy.
Second, we studied the co-medications at start and in the
trailing period. Third, we added the specialty of the
prescriber who prescribed the first osteoporosis drug. Co-
medications were analyzed for ten treatment segments, each
corresponding with one or more therapeutic areas. Some
treatment classes had a relation to osteoporosis (e.g.,
calcium, vitamin D, and glucocorticosteroids) and others
were chronic medication classes for other diseases (e.g.,
cardiovascular diseases)
Follow-up of stoppers
Patients who stopped with the drug of start due to lack of
renewal prescriptions for any oral osteoporosis drug were
selected. As illustrated in Fig. 1, these patients are tracked
for 18 months of which the first 6 months, the trailing
period, serve to measure their stopping on the medication.
The follow-up of these patients is observed during the
connecting period of 12 months in which a new prescrip-
tion for any oral osteoporosis drug is reported. We observed
in our prescription database 38,349 patients receiving a
prescription for an oral osteoporosis drug per month, of
which 35,207 were receiving osteoporosis medication
during the following 6 months. We choose to include these
stoppers for 3 months, resulting in a total group of 9,372
stoppers.
Statistical analysis
Determinants of persistence were analyzed by logistic
multivariate regression model with adjusted odds ratios
(or with 95% confidence interval) using SAS version 9.1.
Statistical significance for the model was defined at an
alpha level of 0.05. The independent covariates were
included by a forward stepwise selection technique with
an entry probability of 0.05. The Hosmer and Lemeshow
Goodness-of-Fit test was used to assess the reliability of the
model [32]. For the significance testing of differences in the
MPR, a univariate logistic regression model was used.
Results
Compliance
The cohort available for evaluating 12-month compliance
included 105,506 patients. On average, the 12-month MPR
of >80% was found in 91% of patients. Compliance was
significantly less than the total mean for etidronic acid
(85.7%), strontium ranelate (79.1%), and ibandronic acid
(89.0%; Table 1). About 10% of all patients had an MPR of
below 80%, and 5% collected more medication than needed
(MPR>120%). Around 85% of the patients had a MPR
between 80% and 120% (Fig. 2).
Persistence
The cohort available for evaluating persistence in starters
consisted of 8,626 patients. The baseline characteristics of
the study population are shown in Table 2. Mean age was
69.2 years (standard deviation, 13.8 years), 80% were
women, 28% had their pharmacy in high densely populated
cities, and 63% of the start prescriptions were from GPs.
Most patients (95%) were receiving medication of other
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Fig. 2 12 months’ compliance (MPR) by product and intake frequency of oral osteoporosis medication
1540 Osteoporos Int (2011) 22:1537–1546Table 2 Baseline characteristics of 8,626 patients and adjusted odds ratios for variables influencing 12 months’ persistence
Patients V% Persistence Adj.OR (95% CI)
a
Total (n, V%) 8,626 43.1%
Age
1, <=60 2,092 24.3% 36.1% Reference
2, 61–70 2,059 23.9% 45.1% 1.41 (1.23–1.61)
3, 71–80 2,591 30.0% 45.7% 1.51 (1.33–1.73)
4, >=81 1,884 21.8% 44.9% 1.64 (1.42–1.90)
Gender
Female 6,900 80.0% 43.9% –
Male 1,726 20.0% 39.7% –
Urbanization
1, very high (densely) 2,464 28.6% 37.9% Reference
2, high 2,584 30.0% 45.4% 1.39 (1.23–1.56)
3, moderate 1,701 19.7% 43.3% 1.30 (1.13–1.49)
4, low 1,401 16.2% 46.9% 1.44 (1.25–1.66)
5, very low (sparsely) 476 5.5% 45.5% 1.37 (1.11–1.70)
GP or specialist of start Rx
GP 5,426 62.9% 45.0% –
Specialist 3,200 37.1% 39.8% –
Start product
Risedronic ac. weekly and daily Ca 747 8.7% 42.4% –
Risedronic ac. 35 mg weekly 1,818 21.1% 45.4% –
Risedronic ac. 5 mg daily 82 1.0% 40.2% –
Alendronic ac. 10 mg daily 241 2.8% 23.2% 0.31 (0.23–0.43)
Alendronic ac. 70 mg weekly 3,698 42.9% 43.4% –
Ibandronic ac. 150 mg monthly 443 5.1% 46.3% –
Etidronate cyclic and daily Ca 281 3.3% 28.5% 0.42 (0.32–0.56)
Raloxifene 60 mg daily 63 0.7% 33.3% 0.53 (0.31–0.92)
Alendronic ac. 70 mg and vitD weekly 965 11.2% 52.7% 1.41 (1.21–1.63)
Strontium ranelate 288 3.3% 21.9% 0.27 (0.20–0.36)
Drug burden in lookback period
0 509 5.9% 43.4% excl.
1, 2 2,584 30.0% 43.1% excl.
3, 4 3,228 37.5% 42.3% excl.
5+ 2,305 37.4% 44.0% excl.
Medication lookback period
With_any_medication 8,153 94.5% 43.1% excl.
Without_any_medication 473 5.5% 42.7% excl.
Osteoporosis 1,221 14.2% 43.3% –
Calcium and/or vit. D 2,408 27.9% 47.4% 1.26 (1.13–1.39)
Statins 1,689 19.6% 45.8% –
Cardiovascular medication 4,551 52.8% 44.0% 0.88 (0.79–0.97)
Anti-inflammatory 2,537 29.4% 46.1% –
Gastric protectors 3,597 41.7% 42.5% –
Asthma/COPD 1,684 19.5% 40.2% –
Diabetic medication 793 9.2% 45.1% –
Antidepressants 961 11.1% 42.2% –
Thyroid hormone 570 6.6% 41.4% –
Glucocorticoids 2,685 31.1% 37.6% 0.65 (0.59–0.72)
Medication trailing period
With_any_med 7,083 82.1% 51.9% 9.31 (7.93–40.92)
Without_any_med 1,543 17.9% 2.3% Reference
V% volume percentage, excl. variables that were excluded from the logistic regression model due to multicollinearity, – non-significant variables
aOdds ratios based on the logistic regression model adjusted for the variables with 95% confidence interval
Osteoporos Int (2011) 22:1537–1546 1541drug classes at the moment they started osteoporosis
medication, of whom 75% had three or more medication
classes prescribed and 37% had five.
The three most frequently prescribed oral drugs for
starters on osteoporosis were alendronic acid 70 mg weekly
(42.9%), risedronic acid 35 mg weekly (21.1%), and the
weekly combination of 70 mg alendronic acid together with
vitamin D3 (11.2%). The three least frequently prescribed
medications were raloxifene (0.7%), risedronic acid 5 mg
(1.0%), and alendronic acid 10 mg (2.8%). After 3 months,
70% of patients were persistent and 43%, after 12 months
(Fig. 3).
Compared to the mean persistence of all medications,
patients using weekly one-tablet alendronic acid 70 mg
combined with 2,800 IU vitamin D3 had the highest
persistence after 12 months (52.7%; OR, 1.41; CI, 1.21,
1.63). Lowest persistence was found with strontium
ranelate (21.9%; OR, 0.27; CI, 0.23, 0.43), daily alendronic
acid 10 mg (23.2%; OR, 0.31; CI, 0.23, 0.43), cyclic
etidronate (28.5%; OR, 0.42; CI, 0.32, 0.56), and raloxifene
(33.3%; OR, 0.53; CI, 0.31, 0.92). Persistence was 23–40%
with daily, 42–53% with weekly, and 46% with monthly
bisphosphonates. One-year persistence was 52% in patients
who also continued other medications compared to 43% in
the total persistence population. In the multivariate analysis,
1-year persistence was higher with increasing age (OR,
1.41 to 1.64, according to age and compared to patients of
60 years and younger), medium-or lower-density urbaniza-
tion (OR, 1.39 to 1.44 compared to lower urbanization as
compared to very high-density urbanization of the patients),
previous use of calcium and/or vitamin D (OR, 1,26; CI,
1.13, 1.39 as compared to no calcium/vitamin D), and use
of multimedication at the start (OR, 9.31; CI, 7.93, 40.92 as
compared to no multimedication). One-year persistence was
lower in users of cardiovascular medication (OR, 0.88; CI,
0.79, 0.97 versus no use) and of glucocorticoids (OR, 0.65;
CI, 0.59, 0.72 versus no use). The sensitivity and specificity
used were both 65% which indicates that, although
significance of individual variables was reached, there were
also other (unknown) factors that influence the persistence.
As can be seen in Table 2 under medication lookback
period, 1,221 patients who were already treated with
osteoporosis medication appeared not to influence the
persistence of a new anti-osteoporosis drug. In other words,
switching to another osteoporosis drug did not influence
persistence.
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The follow-up of non-persistence 18 months after stopping
the medication is shown in Fig. 4. During a further follow-
up of 18 months in non-persistent patients, restart with oral
osteoporosis drugs was found in 22.3%, of whom 85%
restarted the original drug (18.9% of stoppers), and 15%
switched to another oral osteoporosis medication (3.4% of
stoppers), mostly bisphosphonates.
Discussion
This is the largest survey to date on adherence (in terms of
both compliance and persistence) to the whole spectrum of
oral anti-osteoporotic drugs carried out on a national scale
in a routine practice setting. Analyses of this source are
derived from samples of the ongoing IMS Health’s
longitudinal prescription database covering ~11.5 of the
16.5 million community dwelling Dutch residents. This
database differs from another Dutch database called the
PHARMO Record Linkage System that contains pharmacy-
dispensing data of about 2 million residents linked to a
hospital discharge register [33, 34]
Compliance
On average, 91% of the patients taking oral osteoporosis
medication had an MPR of ≥80%, which generally is
considered as the optimal percentage for bisphosphonate
treatment to be effective in preventing fractures [14]. This
MPR is higher than in most other studies. This can be
explained by several reasons. First, the method we used to
calculate the compliance differs from other publications by
including only patients with at least three prescriptions in a
1-year period, whereas in other studies, patients who had
less than three prescriptions or using shorter (90 days) or
even longer study periods of 2 years were included [14,
24]. Thus, our group of patients had already shown
persistence during a relative long time of at least 9 months
over a 12-month period, and could therefore be more
compliant. Second, we included both new patients starting
on osteoporosis medication and existing patients who were
already treated, whereas many studies included only new
patients [14, 25, 33, 35] who have lower persistence than
patients already on treatment. However, as it can be seen in
Table 2 under medication lookback period that 1,221
patients who were already treated with osteoporosis
medication appeared not to influence the persistence of a
new anti-osteoporosis drug. Third, a high compliance could
be specific for the Dutch population as all prescribed
osteoporosis medications including calcium and vitamin D
were reimbursed. Another study on compliance in the
Netherlands using other databases and 3, 6, and 12-month
intervals after start of therapy showed a relatively high
compliance (58%) in patients who started medication,
including also non-persistent patients [34]. Recent compli-
ance data from Sweden with comparable reimbursement
also showed a high MPR with even an average of 94.6% in
a large cohort of patients [36]. When reimbursement is
offered, a patient’s attitude could change to obtain more
frequently prescriptions from physicians and deliveries
from pharmacies. Therefore, different reimbursement rules
could be important in judging the MPR in different parts of
the world.
Persistence
One-year persistence was low (43%), and in line with other
studies from the Netherlands in which persistence of
bisphosphonates was 30–52% [33] and 44% [37]. Siris
and co-workers [14] compared persistence rates in different
studies, mainly in bisphosphonate users, and found a 1-year
persistence ranging from 24% [38] to 61% [35].
As expected and reported by others [29, 33], persistence
was significantly lower for daily than for weekly
bisphosphonates, but also lower for other daily medica-
tions, such as raloxifene and strontium ranelate. Thus, in
spite of the fact that the intake of raloxifene and strontium
ranelate has no restrictions as compared to bisphosphonates
(in terms of staying without food and not lying down for 30
to 60 min), presumably, the daily intake contributes to
lower persistence. The low persistence for strontium
ranelate (21.7%) could additionally be the result of the
warning by the EMEA [39] on the DRESS syndrome which
was associated with two lethal adverse events, which was
also reported in the Dutch lay media. Indeed, from the date
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Osteoporos Int (2011) 22:1537–1546 1543of that announcement (6–9 months after start of the
persistence cohort), persistence dropped from 46% to 22%.
Quite unexpected was the finding that the persistence of
monthly ibandronic acid (46%) was significantly lower than
weekly alendronic acid with vitamin D (53%). This is in
contrast with the PERSIST study [40] in which the 6-month
persistence was 57% with weekly ibandronic acid as
compared to 39% for weekly alendronic acid (p<0.0001),
but was also found in a US prescription database [41], in
which discontinuation with ibandronic acid was 10% higher
than with weekly alendronic acid (p<0.0001). This dis-
crepancy between persistence in clinical studies and in the
field of daily clinical practice underscores the importance of
post-marketing surveillance for persistence.
The low persistence for oral osteoporosis medications is
quite unexpected, taking into account that guidelines for
osteoporosis in the Netherlands were available since 2002,
i.e., some 5 years before this survey [42]. However, in these
guidelines, no advices were given on monitoring treatment
and repeat bone densitometry was discouraged, as at the
time these guidelines were developed (1998–2002), no
studies were available on the effect of clinical or bone
densitometry monitoring on persistence. This resulted in
most patients treated for osteoporosis in a clinical monitoring
vacuum from the start and during many years.
Meanwhile, several studies have shown that persistence
can be improved by clinical monitoring. Adherence is
higher in clinical trials than in daily clinical practice.
Several interventions on patients’ education have been
studied to improve adherence, with small to no results [43,
44]. In a recent randomized controlled study, monitoring in
daily clinical practice after 12, 24, and 36 weeks by a nurse
during a personal contact and using a standardized
questionnaire improved MPR (>75%) from 42% (CI, 22–
62%) without monitoring to 65% (CI, 52–79%) with
clinical monitoring (p=0.04) [45]. Measuring bone markers
did not improve MPR in that study. In a 1-year persistence
study with risedronate which included a doctor’s visit after
13 and 15 weeks, persistence was 80% [46]. This
persistence was considered unexpectedly high, but was
probably just the result of clinical monitoring by the doctor.
Persistence could thus be improved by clinical monitoring
with personal nurse–patient or doctor–patient visits. Clin-
ical research is indicated on how to further optimize
persistence. A hopeful novel intervention by motivational
interviewing is now investigated in a blinded randomized
controlled trial [47].
Factors related to non-persistence
Several characteristics of non-persistence could be identi-
fied. Apart from the differences in persistence according to
medications, differences were also found in other factors
that could be analyzed. However, even in patients with
factors that contributed significantly to higher persistence,
the persistence remained low (e.g., >45–46% in patients
older than 60 years compared to 36% in patients younger
than 60 years). Even in patients with the most strong
positive odds ratio (multimedication during follow-up), the
persistence was 52%. Remarkably, persistence was signif-
icantly lower in glucocorticoid users (38%). One would
expect a much more favorable adherence for osteoporosis
drugs because of the negative effects of glucocorticoids
on bone. On the other hand, the use of bisphosphonates
could worsen gastric adverse events caused by glucocorti-
coids. Rossini and co-workers [48] from Italy described
positive associations between glucocorticosteroid and
anti-inflammatory treatment for the compliance with
osteoporosis medication. They found on the other hand a
decrease of the compliance of osteoporosis drug usage in
patients on benzodiazepines or gastro-protective drugs. An
important difference with our study is that we studied
medications which were prescribed during 6 months
before the start of the osteoporosis treatment and not
necessarily during this treatment.
Follow-up after non-persistence
During 18 months after stopping in the last 12 months, 78%
of the patients still didn’t restart osteoporosis drugs.
Switching between treatments was almost limited to
switching from one bisphosphonate to another. In most
studies on adherence of chronic oral treatments, stopping of
medication is almost an endpoint, without analyzing how
long patients stop, or restart or switch. Almost no literature
is available about restarting osteoporosis medication after
the first prescription year. In the US, Brookhart and
colleagues [25] described in a group of elderly women
with low or moderate income the restart of osteoporosis
medication. They found that of the patients who stopped
therapy for 60 days, an estimated 30% restarted treatment
within 6 months, and 50% within 2 years. Patients who stop
medication for only 60 days are possibly more motivated to
restart. However, they did not report separately restart of
medication in patients who stopped medication during
longer follow-up.
The strengths of the study are the extensive representative
data source, nationwide coverage, and the multiple regression
on non-persistence so that reliable conclusions can be drawn.
We also detected factors that were related to compliance and
non-compliance, and which explained 65% of the variance in
persistence. The clinical implications of our findings deserve
further studies to optimize adherence. It will be important in
futurestudies toprolongthe follow-uptimeofpersistence and
non-persistence,tostudyinprospectivetrialsfactorsrelatedto
patients and doctors that contribute to compliance, and to link
1544 Osteoporos Int (2011) 22:1537–1546the pharmacy data to osteoporosis history, diagnosis, and
clinicalfollow-up.Calculatingapredictivemodelthatdelivers
the types of patients having the best and the worst prognosis
on persistence can be of great help for physicians. Other
additionalresearchhastobefocusedonabetterunderstanding
of the significantly lower persistence of patients treated with
glucocorticosteroids and influence of other co-medications.
This study has also several limitations. First, the
retrospective character of the design could cause bias.
Moving to another address (e.g., nursing home) or death
during follow-up could have biased the persistence results.
Indeed, persistence for osteoporosis medication was 52% in
patients who also continued other medications, compared to
43% in the total persistence population, but persistence
curves of the individual osteoporosis medications were
comparable between these groups (data not shown).
However, since especially younger patients had lowest
persistence, underestimation of persistence due to death or
moving to other locations such as nursing home is unlikely.
Even taking into account the more conservative number of
patients with concurrent medication, the persistence was
low. Second, the appropriateness of osteoporosis medica-
tion could not be analyzed because no information on
fracture or bone mineral density was present in the database
used. Third, no knowledge about the reason for stopping
treatment is available. Such information will be of great
importance in future research. Fourth, no information is
available about the medical history whether the drug is
taken correctly at the correct time of the day, too large
doses to compensate for forgotten doses, pill dumping or
stockpiling, etc. as these aspects were not part of the study
design. Fifth, branded and generic alendronic acid could not
be distinguished. This could be of importance since it was
suggested that persistence of generic alendronic acid was
poorer [49, 50]. Sixth, no data on intravenous or subcuta-
neous osteoporosis treatments could be analyzed because
these drugs are either delivered to the patients in the
hospital or by special ambulatory pharmacies. However, at
the time of the study, zoledronate was only scarcely used.
Seventh, it could not be taken into account if stoppers only
visited the pharmacy for osteoporosis medication or also
visit the pharmacy for other medications after stopping. The
actual percentage of patients who stopped during the 18-
month follow-up might therefore be lower. However, at the
time of the investigation, intravenous bisphosphonates or
subcutaneously teriparatide injections were only scarcely
used, but no data were available on eventual death as the
patients were anonymized.
In conclusion, compliance in non-switching and persis-
tent patients was >90%, but more than half of the patients
starting oral medication for osteoporosis were non-
persistent within 1 year, and 78% of the non-persistent
patients did not restart or switch to other treatment
regimens during a further follow-up of 18 months. These
data indicate a major failure to adequately treat patients at
high risk for fractures in daily clinical practice.
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